Research Article Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial Sarfraz Ahmed , 1 Najeeb Ullah, 2 Sadia Parveen, 2 Ifra Javed, 2 Nur Asyilla Che Jalil, 3 Mogana Das Murtey, 4 Irfan Shahzad Sheikh, 5 Shahroz Khan, 6 Suvash Chandra Ojha , 7,8 and Ke Chen 7,8 1 Department of Basic Sciences, University of Veterinary and Animal Sciences Lahore, 51600 Narowal, Pakistan 2 Department of Biochemistry, Bahauddin Zakariya University, Multan 60800, Pakistan 3 Departments of Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia 4 Basic Sciences and Oral Biology Unit, School of Dental Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia 5 Centre for Advanced Studies Vaccinology and Biotechnology, University of Balochistan, Quetta, Pakistan 6 Noor Nursing College, Swari, 19290 Buner, Pakistan 7 Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, 646000 Luzhou, China 8 Southwest Medical University, Jiangyang District, Luzhou, 646000 Sichuan, China Correspondence should be addressed to Suvash Chandra Ojha; suvash_ojha@swmu.edu.cn and Ke Chen; chitty8705@sina.com Received 21 November 2021; Accepted 29 December 2021; Published 2 February 2022 Academic Editor: Jianbo Xiao Copyright © 2022 Sarfraz Ahmed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Silymarin is proclaimed to be a blend of flavonolignans or phytochemicals. An era of new generation of direct-acting antivirals (DAAs) has commenced to have facet effect in swaying of the hepatitis C virus (HCV). Nonetheless, this therapy has serious side effects that jeopardize its efficacy. This study is aimed at probing the effects of ribavirin (RBV) and sofosbuvir (SOF) along with silymarin as an adjunct therapy on hematological parameters and markers of obscured oxidative stress. The effect of DAAs along with silymarin was also examined on variable sex hormone level and liver function markers such as alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and bilirubin. The study was followed to determine viral load and viral genotypes. A total of 30 patients were randomly divided into two equal groups comprising the control group (n = 15) and treatment group (n = 15). The control group was solely administered with DAAs (SOF and RBV; 400 mg/800 mg each/day). Conversely, the treatment group was dispensed with DAAs, but with adjunct therapy of silymarin (400 mg/day) along with DAAs (400/800 mg/day) over period of 8 weeks. Sampling of blood was performed at pre- and posttreatment levels for the evaluation of different propound parameters. Our data showed that silymarin adjunct therapy enhances the efficiency of DAAs. A decrease in menace level of liver markers such as ALT, ALP, AST, and bilirubin was observed (p >0:05). The adjunct therapy concurrently also demonstrated an ameliorative effect on hematological indices and oxidative markers, for instance, SOD, TAS, GSH, GSSG, and MDA (p <0:05), diminishing latent viral load. The silymarin administration was also found to revamp the fluster level of sex hormones. Our outcomes provide evidence that systematic administration of silymarin effectively remits deviant levels of hematological, serological, hormonal, and antioxidant markers. This demonstrates a possibly unique role of silymarin in mitigating hepatitis C. Hindawi Oxidative Medicine and Cellular Longevity Volume 2022, Article ID 9199190, 14 pages https://doi.org/10.1155/2022/9199190